Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07646626

SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Locally Advanced (Unresectable) or Metastatic Solid Tumors

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

About this study

This study includes 2 Parts: Part 1 (SSGJ-705 Plus SSGJ-612 for advanced cancer that have failed standard treatment), and Part 2 (SSGJ-705 or SSGJ-705 Plus SSGJ-612 in combination with chemotherapy for previously untreated advanced gastric cancer).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and/or females over age 18
  • Histologically and/or cytologically documented local advanced or metastatic Colorectal adenocarcinoma (CRC), Urothelial Cancer (UC), Breast Cancer (BC), Biliary Tract Carcinoma(BTC), Gastric/Gastroesophageal Junction Cancer （G/GEJC) , etc.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Expected survival >3 months.
  • Signed informed consent form.

Exclusion criteria

  • Any remaining adverse events (AEs) > grade 1 from prior anti-tumor treatment as per Common Terminology Criteria for Adverse Events（CTCAE） v6. 0, with exception of hair loss, fatigue, and grade 2 peripheral neurotoxicity.
  • Pregnant or nursing women or women/men who are ready to give birth
  • symptomatic central nervous system metastasis.
  • Allergy to other antibody drugs or any excipients in the study drugs.
  • Inadequate organ or bone marrow function. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Treatment and study plan

SSGJ-705

Drug

anti-PD-1 and anti-HER2 bispecifc antibody

SSGJ-612

Drug

anti-HER2 antibody

SSGJ-705 combined with chemotherapy

Drug

SSGJ-705 combined with chemotherapy

Primary outcomes

  1. Objective response rate (ORR)

    Time frame: 12 months

    The primary efficacy end point

  2. Incidence of Treatment-Emergent Adverse Events

    Time frame: 12 months

    The primary safety end point

  3. Severity of Treatment-Emergent Adverse Events

    Time frame: 12 months

    The primary safety end point

Secondary outcomes

  1. Progression-Free-Survival (PFS)

    Time frame: 24 months

    The secondary efficacy end point

Study contacts

Contact information is provided by the study sponsor or research team.

Jieer Ying, M.D.

CONTACT

[email protected]

+86-13858195803

Meifang Zheng, M.D.

CONTACT

[email protected]

+86-15258894828

Sponsors and collaborators

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.

Industry

Registry information

Official study title

A Phase II Study of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Jun 15, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.